Neuralstem Reports First Patient Treated In China Stem Cell Trial to Treat Stroke Motor Deficits
January 13, 2014 at 09:49 AM EST
Neuralstem (NYSE MKT: CUR ) announced that the first patient was treated in the Phase I/II NSI-566 stem cell trial to treat motor deficits from ischemic stroke at BaYi Brain Hospital in Beijing, China. The patient received treatment on December 27, 2013 and has now returned home. The
